DUALITYBIO-B (09606) achieved revenue of approximately 1.852 billion yuan in 2025, making significant progress in pipeline development and business operations.

DUALITYBIO-B (09606) announced its performance in 2025, with revenue of approximately 1.852 billion yuan, gross profit of approximately 589 million yuan, research and development expenditure of approximately 838 million yuan, an increase of 0.12% compared to the previous year. As of now, the group has 10 ADC pipeline products in clinical stages, with over 3,200 patients enrolled in clinical trials globally. This includes over 1,200 patients enrolled in 2025 alone, with approximately 50% of them from regions outside of the US, EU, Australia, and China. In 2025, the company's core product DB-1303 successfully achieved the primary endpoint in the phase 3 registration trial in China and has submitted the application for market approval; DB-1311 has shown excellent efficacy in multiple indications such as prostate cancer and cervical cancer, with global phase 3 trials set to begin; DB-1310 has received two expedited pathways from the US FDA and its clinical value is recognized by international authorities. According to the group's global strategy, the company has established strategic partnerships to accelerate the development of its pipeline in major global markets, expand global clinical development capabilities, and drive future innovation and long-term growth. So far, the company has signed multiple licensing and collaboration agreements with leading companies in the industry globally, including partnerships with BioNTech (for Pasukizumab monotherapy (DB-1303), DB-1311, and DB-1305), BEONE MEDICINES (for DB-1312), Adcendo (for ADC assets using the company's proprietary linkers-payloads), GSK (for DB-1324), and Avenzo (for DB-1418), with a total transaction value exceeding 6 billion US dollars.